
Ind-Swift Labs: consolidated PAT jumps 181% YoY to ₹24.68 Cr on sharp margin expansion
Ind-Swift Laboratories' consolidated net profit for Q1 FY27 (quarter ended June 30, 2026) jumped 181% year-on-year to ₹24.68 Cr from ₹8.77 Cr, well ahead of the 25.4% YoY rise in revenue to ₹191.45 Cr (from ₹152.73 Cr). Sequentially, revenue grew 12.8% and PAT rose 63% over Q4 FY26. Standalone tells the same story — PAT of ₹24.44 Cr, up ~201% YoY on revenue of ₹186.08 Cr — the ~20-point gap versus consolidated growth traces to joint-venture consolidation scope rather than any divergence in the underlying operating story. The gain is almost entirely margin-led: consolidated OPM (EBITDA margin) expanded to roughly 17.5% from just 2.36% a year ago and 9.08% last quarter, with standalone EBITDA at ₹33.32 Cr against ₹8.44 Cr in Q1 FY26 (per the company's own disclosure). Consolidated NPM rose to ~12.9% from 5.24% YoY. A net exceptional loss of ₹0.24 Cr (₹23.58 Lakh, balances written back/off) was booked this quarter versus nil a year ago, but it is too small to move the growth number — adjusted PAT growth is ~184% YoY, effectively unchanged from the reported 181%. There is no analyst consensus or brokerage preview available for this stock, and the company has issued no formal forward guidance on record, so the print can only be judged against its own trend — a clear multi-quarter margin re-rating (OPM: 2.36% → 9.08% → 17.5%) rather than a one-off spike. Management's own note attributes the quarter to higher EBITDA generation but gives no line-by-line driver beyond the EBITDA and PAT figures disclosed. Alongside the results, the board approved sale of a ~10-acre non-operational land parcel in Derabassi for ₹17.50 Cr (to be realised over 9 months) — unconnected to this quarter's operating performance — while the company is separately progressing a ₹137.2 Cr preferential warrant issue to the promoter group and a ₹40 Cr warehouse-construction MoU, pointing to an active capital-raising and capacity-expansion phase running alongside the margin improvement.
Key Highlights
- Consolidated PAT surges 181% YoY to ₹24.68 Cr (from ₹8.77 Cr) and 63% QoQ, on revenue of ₹191.45 Cr, up 25.4% YoY and 12.8% QoQ
- Consolidated OPM (EBITDA margin) expands sharply to ~17.5% from 2.36% YoY (standalone EBITDA ₹33.32 Cr vs ₹8.44 Cr a year ago); NPM up to ~12.9% from 5.24%
- Standalone PAT ₹24.44 Cr, up ~201% YoY, closely tracking the consolidated print
- A net exceptional loss of ₹0.24 Cr (₹23.58 Lakh, balances written off) was booked this quarter — immaterial; adjusted PAT growth is ~184% YoY, effectively unchanged from reported
- EPS (basic) ₹2.84 consolidated / ₹2.81 standalone for the quarter, up from ₹1.17 / ₹1.18 a year ago
- Same-day board action: approved sale of a ~10-acre non-operational land parcel in Derabassi, Punjab for ₹17.50 Cr, realised over 9 months — unrelated to this quarter's operating P&L
- Company is progressing a ₹137.2 Cr preferential warrant issue to the promoter group (70 lakh warrants) and signed a ₹40 Cr MoU for warehouse construction, pointing to a capacity/capital-raising phase
Price Impact
More from INDSWFTLAB